Navigation Links
Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Date:9/24/2007

FRAMINGHAM, Mass., Sept. 24 /PRNewswire/ -- Iodine has been used as an antimicrobial for the last century. Much has been written about molecular iodine yet many women suffering from Fibrocystic Breast Disease (FBD) are unaware that studies being conducted may soon yield an effective nonhormonal treatment.

While there are several breast cancer drugs on the market, all available hormonal therapies have significant adverse events. In contrast, IoGen is a nonhormonal treatment that allows for safe long-term use with little or no side effects.

"Current research provides substantive support for the initiation of human clinical studies on the use of molecular iodine as a treatment for breast disease," stated Paul Desjourdy, President and CEO, Symbollon Pharmaceuticals, Inc. "The possibility that IoGen may be used as a treatment for breast cancer makes it all the more important that we expedite the commercialization time line."

The Company believes IoGen has the ability to eliminate excess cell growth in female reproductive tissue, including the breast, ovaries and uterus. Other indications for IoGen include the treatment or prevention of endometriosis, ovarian cysts, and premenopausal breast cancer.

Symbollon Pharmaceuticals, Inc. is now in FDA Phase III clinical trials for the evaluation of IoGen (I2) for pain/tenderness associated with FBD and with potential to treat female reproductive organ cancers.

The importance of (I2) in the treatments for mammary gland dysfunctions has been corroborated in human and animal models.

Seaweeds, containing high quantities of iodine in several chemical forms including (I2), have been associated with low incidences of benign and malignant breast disease in Asian women.

Past studies by independent researchers have supported the possible effectiveness of molecular iodine (I2) as a treatment for breast cancer.

-- Researchers at Drexel University College of Medicine found that

m
'/>"/>

SOURCE Symbollon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
8. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
9. Genetic Analysis Systems Enter the Clinical Mainstream
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... SHENZHEN, China, Nov. 26, 2014 China Nepstar ... the "Company"), a leading retail drugstore chain in China ... announced its unaudited financial results for the third quarter ... ended September 30, 2014: , Same store sales increased ... , Revenue increased by 8.1% to RMB738.3 million (US$120.3 ...
(Date:11/24/2014)... , Nov. 24, 2014 Luoxis Diagnostics, ... MKT: AMPE), today announced the presentation of three ... System as a broadly applicable and robust research ... the body in response to injury, illness, or ... in collaboration with Luoxis, academic and pharmaceutical research ...
(Date:11/24/2014)... CLEVELAND , Nov. 24, 2014  Surgical Theater, ... at the November 24 th opening of ... IRCCS Istituto Neurologico Nazionale "C. Besta." The SuRgical Planner ... be showcased at the event for their 3D navigation ... Dr. Joshua Bederson , Professor and Chair, Department ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... 20, 2011 Robbins & Myers, Inc. (NYSE: ... first quarter fiscal 2012 ending November 30, 2011 before the ... 9:00 a.m., CT / 10:00 a.m., ET on January 6.  ... J. Brown, Interim Chief Financial Officer & Corporate Controller, will ...
... HACKENSACK, N.J., Dec. 20, 2011 In an ... error rates, HackensackUMC recently announced the implementation of ... SurgiCount Safety-Sponge®  is a product of SurgiCount Medical, ... Technologies, Inc. (OTCBB:PSTX, OTCQB:PSTX). This system provides a ...
Cached Medicine Technology:HackensackUMC Adopts SurgiCount Safety-Sponge® System 2HackensackUMC Adopts SurgiCount Safety-Sponge® System 3
(Date:11/26/2014)... HILLS, CA (PRWEB) November 26, 2014 With ... costing thousands of dollars, the prosthodontists at the Anacapa Dental ... paying for dental procedures can be daunting for some. , ... pay for the procedures they offer. , “No dentist wants ... and beautiful set of teeth,” said Dr. Mamaly Reshad, partner ...
(Date:11/26/2014)... 26, 2014 ISI Telemanagement Solutions, ... has been award the 2014 Lync Pioneer ... award comes as a great honor to ISI, ... Lync ecosystem. Specifically, ISI offers an integrated collaboration ... Lync communication, including voice, video, Lync IM, and ...
(Date:11/26/2014)... 26, 2014 Bunion Bootie, the newest ... in an early celebration of the early holiday shopping ... offered at the promotional price of $29.95 each (normally ... addition to any automatic discounts applied when buying more ... website for complete details. It’s simple: purchasing more ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. Hill, ... from The American Association of Nurse Practitioners ... nurse practitioners. The Distinguished Preceptorship Award recognizes the ... significant contribution toward increasing the awareness and acceptance ... (AANP) is the largest full-service national professional membership ...
(Date:11/26/2014)... Teens prescribed anti-anxiety or sleep medications are much ... teens, a new study warns. The findings ... on teenagers before prescribing these drugs to them, ... realize the abuse potential," said lead researcher Carol ... School of Nursing. "These drugs produce highly attractive ...
Breaking Medicine News(10 mins):Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... Doctors more often tell younger people to change diet, get ... -- Americans over 60 with high blood pressure are less ... on how lifestyle changes can lower their blood pressure, a ... North Carolina at Chapel Hill analyzed data from a U.S. ...
... Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical",or ... high-quality,pharmaceutical grade glucose products in China, today reported ... 2007. First Quarter of Fiscal 2008 Highlights ... $19.4 million -- Gross profit rose ...
... PORTLAND, Ore., Nov. 15 Every year more,holiday ... will stand,out above the rest while helping families ... organization, has taken this,charitable holiday gift-giving approach to ... http://www.mercycorps.org . Mercy Kits give people ...
... Va., Nov. 15 With the holidays,quickly approaching, ... As decorations go up, extension cords will be ... The Electrical Safety Foundation,International (ESFI) urges you to ... improper use can pose serious shock and fire ...
... Approved for Retreating Both Hepatitis ... C Relapsers and Nonresponders, ... today announced that the European Commission on,October 30 approved 48-week ... (ribavirin, 800 - 1,400 mg,daily) combination therapy for retreating adult ...
... life is one key factor to avoiding a number of ... University of Arizona and the University of Wisconsin, Madison, indicates ... have a strong relationship are more likely to delay the ... in the Norton School of Family and Consumer Sciences at ...
Cached Medicine News:Health News:Older Hypertension Patients Less Likely to Get Lifestyle Advice 2Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 11Health News:Online Charitable Holiday Giving: Making a Difference with the Gifts You Give 2Health News:Holiday Decorating and Extension Cords 2Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 2Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 3Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 4Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 5Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 6Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 7Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 8Health News:Girls will be girls longer when home life is stable 2
... The VASER System represents a ... ultrasonic technology to cosmetic procedures. Combined ... selective tissue emulsification, a solid grooved ... the VASER System has been designed ...
... The next generation of the ... PSI-TEC III retains all the ... PSI-TEC a leading name for,aspiration ... flow,vacuum pumps for high powered ...
Richardson Retractor...
Our most popular saline breast implant style for over 20 years. A full, rounded look that adds greater dimension to the breast....
Medicine Products: